# AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-imfinzi-plus-chemotherapy-approved-in-the-us-for-endometrial-cancer/4121160459
- Published: 2024-06-17T07:25:59+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Imfinzi_ (durvalumab) in combination with carboplatin and paclitaxel followed by
_Imfinzi_ monotherapy has been approved in the US as treatment for adult patients
with primary advanced or recurrent endometrial cancer that is mismatch repair deficient(
dMMR).^(1)

The approval by the Food and Drug Administration (FDA) was based on the results 
of a prespecified exploratory subgroup analysis by MMR status in the DUO-E Phase
III trial. Results from DUO-E were published in the Journal of Clinical Oncology.

In the trial, _Imfinzi_ plus carboplatin and paclitaxel followed by _Imfinzi_ monotherapy(
_Imfinzi_ arm) reduced the risk of disease progression or death by 58% in patients
with dMMR endometrial cancer versus chemotherapy alone (hazard ratio 0.42; 95% confidence
interval 0.22-0.80).^(2)

In the US, endometrial cancer is the fourth most common cancer in women, with more
than 66,000 patients diagnosed and almost 12,000 deaths in 2022.^(3,4) Patients 
diagnosed at an early stage of disease have a five-year survival rate of approximately
80-90%, but there is a significant need for new treatment options for people with
advanced disease, where the survival rate falls to less than 20%.^(5,6)

> **Shannon N. Westin, Professor of Gynecologic Oncology and Reproductive Medicine
> at The University of Texas MD Anderson Cancer Center, and principal investigator
> of the trial, said,** “With the incidence and mortality of endometrial cancer 
> expected to continue to increase significantly in the coming decades, it is more
> important than ever that we bring new treatment options to patients at the earliest
> possible moment in their care. This approval underlines clear evidence that durvalumab
> plus chemotherapy followed by durvalumab monotherapy delivers important clinical
> benefits for patients with mismatch repair deficient endometrial cancer.”

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca,
> said:** “There have been limited advances in the treatment of endometrial cancer
> in the last few decades, and continued innovation is critical as the burden of
> this cancer is expected to grow in the future. Immunotherapy in combination with
> chemotherapy is emerging as a new standard of care in this setting, and the approval
> of _Imfinzi_ offers an important new option for patients with mismatch repair 
> deficient disease.”

The safety and tolerability profile of the _Imfinzi_ and chemotherapy regimen was
generally manageable, well tolerated and broadly consistent with prior clinical 
trials with no new safety signals.^(1,2)

The _Lynparza_ (olaparib) and _Imfinzi_ arm, which investigated _Imfinzi_ plus chemotherapy
followed by _Imfinzi_ plus _Lynparza_ as maintenance therapy, also met the primary
endpoint of progression-free survival (PFS). The trial continues to assess OS as
a key secondary endpoint for both arms. Regulatory applications for both _Imfinzi_
as well as _Imfinzi_ and _Lynparza_ regimens are currently under review in the EU,
Japan and several other countries based on the DUO-E results.

Share on:
